Japan Tobacco Group (JT) operates in all four Index Regions, and in 34 of the 36 Index Countries. Its top five countries by Volume Sales are Japan, Russia, Turkey, the UK and Italy.
JT operates across HMICs (24 Index Countries) and LMICs (10 Index Countries).
JT’s product portfolio consists of cigarettes, fine cut tobacco, cigarillos, shisha, heated tobacco, e-liquids, pipe tobacco, closed system vaping products, cigars, snus, and non-tobacco nicotine pouches.
"Smoking is a cause of serious disease including lung cancer, coronary heart disease, emphysema and chronic bronchitis. JT supports efforts to advise smokers accordingly. Everyone should be appropriately informed about the health risks of smoking. Reduced-Risk Products: We believe products that do not involve combustion and do not produce tobacco smoke are products with the potential to reduce the risks associated with smoking. We are committed to developing and bringing to market Reduced-Risk Products that meet consumer expectations.”
(JT corporate website, “Our Six Core Principles”)
JT’s Strategy and Management category score increased as JT announced in 2021 that for the first time the board's bonus would partly (10% of the total) depend on RRP performance.
JT’s Product Sales and Product Offer category scores declined following the company’s decision to withdraw its closed system vaping product (Logic) from Ukraine in January 2021, citing a “lack of demand”.
JT’s Product Sales category score was also negatively impacted by the company’s increasing (CAGR 2019-2021: +0.8%) HRP Volume Sales.
ppts = Difference in percentage between 2021 and 2019
*Japan Tobacco Group is publicly traded but the Government of Japan owns 33.3% of the company.
To search, type what you're looking for and results will appear automatically